NDC 63323-322-01 - Imipenem and Cilastatin
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 63323-322
- Requested NDC
- 63323-322-01
- Package NDCs from labels
- 63323-322-21, 63323-322-93, 63323-322-41, 63323-322-94, 63323-322-01, 63323-322-25
- Manufacturer
- Fresenius Kabi USA, LLC | ACS Dobfar S.p.A. | Zambon Switzerland Ltd
- Effective date
- 2022-10-11
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| IMIPENEM - Fresenius Kabi USA, LLC | ACS Dobfar S.p.A. | Zambon Switzerland Ltd | Fresenius Kabi USA, LLC | ACS Dobfar S.p.A. | Zambon Switzerland Ltd | 2022-10-11 | HUMAN PRESCRIPTION DRUG LABEL |
| IMIPENEM - Fresenius Kabi USA, LLC | ACS Dobfar S.p.A. | Zambon Switzerland Ltd | Fresenius Kabi USA, LLC | ACS Dobfar S.p.A. | Zambon Switzerland Ltd | 2022-10-10 | HUMAN PRESCRIPTION DRUG LABEL |
| IMIPENEM - Fresenius Kabi USA, LLC | ACS Dobfar S.p.A. | Zambon Switzerland Ltd | Fresenius Kabi USA, LLC | ACS Dobfar S.p.A. | Zambon Switzerland Ltd | 2022-10-06 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 63323-322-01 | Imipenem and Cilastatin | 20 mL in 1 VIAL, SINGLE-DOSE | INJECTION, POWDER, FOR SOLUTION | 20 | 12 | |
| 63323-322-25 | Imipenem and Cilastatin | 25 in 1 CARTON | INJECTION, POWDER, FOR SOLUTION | 25 | 12 | |
| 63323-322-41 | Imipenem and Cilastatin | 20 mL in 1 VIAL, SINGLE-DOSE | INJECTION, POWDER, FOR SOLUTION | 20 | 7 | |
| 63323-322-94 | Imipenem and Cilastatin | 25 in 1 CARTON | INJECTION, POWDER, FOR SOLUTION | 25 | 7 | |
| 63323-322-21 | Imipenem and Cilastatin | 20 mL in 1 VIAL, SINGLE-DOSE | INJECTION, POWDER, FOR SOLUTION | 20 | 5 | |
| 63323-322-93 | Imipenem and Cilastatin | 25 in 1 CARTON | INJECTION, POWDER, FOR SOLUTION | 25 | 5 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 63323-322 | IMIPENEM AND CILASTATIN (IMIPENEM AND CILASTATIN SODIUM) INJECTION, POWDER, FOR SOLUTION [FRESENIUS KABI USA, LLC] | 12 | Current NDC, Legacy NDC, 2 package rows | 20221020_6ab0ca9e-9a79-4cab-9f09-470eda06952e.zip |
| 63323-322 | IMIPENEM AND CILASTATIN (IMIPENEM AND CILASTATIN SODIUM) INJECTION, POWDER, FOR SOLUTION IMIPENEM AND CILASTATIN (IMIPENEM AND CILASTATIN SODIUM) INJECTION, POWDER, FOR SOLUTION [FRESENIUS KABI USA, LLC] | 7 | Current NDC, Legacy NDC, 2 package rows | 20221027_0a1dd9b9-ada1-4bff-9dcb-18961254e9e8.zip |
| 63323-322 | IMIPENEM AND CILASTATIN (IMIPENEM AND CILASTATIN SODIUM) INJECTION, POWDER, FOR SOLUTION IMIPENEM AND CILASTATIN (IMIPENEM AND CILASTATIN SODIUM) INJECTION, POWDER, FOR SOLUTION [FRESENIUS KABI USA, LLC] | 5 | Current NDC, Legacy NDC, 2 package rows | 20221103_ce771566-c4f2-447e-944a-6b908925c90b.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 63323-322-01 | EA - Each | 63323-322 | 34deeaf8-735f-4d5d-8ce0-f7bca735d05f | 1 | 2022-01-06 |
| 63323-322-20 | EA - Each | 63323-322 | 15d13752-d665-47b7-a49c-deac99c4cf15 | 1 | 2012-07-24 |
| 63323-322-21 | EA - Each | 63323-322 | f295eda5-5f73-456c-93a6-9c36771eb017 | 1 | 2022-04-06 |
| 63323-322-25 | EA - Each | 63323-322 | 3224fb37-f888-4ac9-943f-4fd3d043976d | 1 | 2013-02-13 |
| 63323-322-41 | EA - Each | 63323-322 | 1036c74b-ed3a-40f7-bbf1-87d3249cda17 | 1 | 2022-10-06 |
| 63323-322-93 | EA - Each | 63323-322 | 09ffc170-6c97-4df2-939c-49e83a8a41f7 | 1 | 2016-07-19 |
| 63323-322-94 | EA - Each | 63323-322 | 89f6cade-0bdd-4c18-b4ce-d0e9ff9c7655 | 1 | 2015-01-05 |
DailyMed Socrata Ingredients#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Market Basket Effervescent Antacid and Pain Relief | ASPIRIN, CITRIC ACID, SODIUM BICARBONATE | Demoulas Super Markets, Inc. | e15439c7-0e3c-7752-e053-2995a90a1a40 | 2026-05-11 | Warnings | 8MDF5V39QO |
| Meijer Effervescent Antacid and Pain Relief | ASPIRIN, ANHYDROUS CITRIC ACID, SODIUM BICARBONATE | Meijer Distribution Inc | 7305972b-aa0f-4daa-e053-2991aa0adfd7 | 2026-05-11 | Warnings | 8MDF5V39QO |
| Sodium Bicarbonate | SODIUM BICARBONATE | Vitamex USA, Corp | 5195cab5-bdda-2ddf-e063-6394a90ac9fe | 2026-05-11 | Warnings | 8MDF5V39QO |
| Sodium Bicarbonate | SODIUM BICARBONATE | TWIN MED LLC | 0f867f56-4bc0-4a85-b9d2-a16282b7c82b | 2026-05-01 | Warnings | 8MDF5V39QO |
| Arm and Hammer Baking Soda | SODIUM BICARBONATE | Church & Dwight Co., Inc. | 643fe204-4a7b-00e4-e053-2a91aa0aef06 | 2026-04-21 | Warnings | 8MDF5V39QO |
| SODIUM BICARBONATE | SODIUM BICARBONATE | Medical Purchasing Solutions, LLC | 4f97d398-2118-0874-e063-6394a90a4ad1 | 2026-04-16 | Warnings, Adverse reactions | 8MDF5V39QO |
| PEG 3350 and Electrolytes | POLYETHYLENE GLYCOL 3350, SODIUM SULFATE ANHYDROUS, SODIUM BICARBONATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE | Wilshire Pharmaceuticals, Inc. | b251752d-7750-482a-9364-0acf4ad47cc8 | 2026-04-16 | Warnings, Adverse reactions | 8MDF5V39QO |
| GoLYTELY | POLYETHYLENE GLYCOL 3350, SODIUM SULFATE ANHYDROUS, SODIUM BICARBONATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE | Azurity Pharmaceuticals, Inc. | 7609ecf7-0ce0-4fbb-9c27-30987f689575 | 2026-04-15 | Warnings, Adverse reactions | 8MDF5V39QO |
| TRILYTE | POLYETHYLENE GLYOCOL 3350, SODIUM CHLORIDE, SODIUM BICARBONATE AND POTASSIUM CHLORIDE | Aurobindo Pharma Limited | 79f5e596-8d51-4227-afcc-f5e341150957 | 2026-04-15 | Warnings, Adverse reactions | 8MDF5V39QO |
| PEG 3350, sodium chloride, sodium bicarbonate and potassium chloride | POLYETHYLENE GLYCOL 3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE | Wilshire Pharmaceuticals, Inc. | 4e442a72-b13b-4869-8a1d-59356095b091 | 2026-04-14 | Warnings, Adverse reactions | 8MDF5V39QO |
| Sodium Bicarbonate 10 gr. (650 mg) | SODIUM BICARBONATE | Gendose Pharmaceuticals, LLC | 0a0cc46d-372e-4175-932a-065e82d8d353 | 2026-04-13 | Warnings | 8MDF5V39QO |
| Sodium Bicarbonate | SODIUM BICARBONATE | Hospira, Inc. | ea9f4498-0d43-4043-8dd1-f22537841c21 | 2026-04-06 | Warnings, Adverse reactions | 8MDF5V39QO |
| Sodium Bicarbonate | SODIUM BICARBONATE | Hospira, Inc. | 8664c7ce-707b-4c6c-9ce4-7160b5f877f8 | 2026-04-06 | Warnings, Adverse reactions | 8MDF5V39QO |
| Omeprazole/Bicarbonate | OMEPRAZOLE AND SODIUM BICARBONATE | Proficient Rx LP | 4d642036-7175-4f29-9f07-dbd282231d4a | 2026-04-01 | Warnings, Adverse reactions | 8MDF5V39QO |
| Rapidol Sodium Bicarbonate | SODIUM BICARBONATE | Pharmadel LLC | b4c9a653-6f51-7c98-e053-2995a90ada37 | 2026-03-26 | Warnings | 8MDF5V39QO |
| Sodium Bicarbonate Antacid | SODIUM BICARBONATE | Aphena Pharma Solutions - Tennessee, LLC | bba7d5bf-c94b-4ee4-a399-9a2818d84c78 | 2026-03-23 | Warnings | 8MDF5V39QO |
| equate omeprazole and sodium bicarbonate | OMEPRAZOLE, SODIUM BICARBONATE | WALMART INC. | c24c3326-99da-4c7d-aecc-7b4a8ac3f04e | 2026-03-15 | Warnings | 8MDF5V39QO |
| SODIUM BICARBONATE | SODIUM BICARBONATE | Hospira, Inc. | 084f5572-8c1f-4802-b179-ca0cc838fc68 | 2026-03-09 | Warnings, Adverse reactions | 8MDF5V39QO |
| Sodium Bicarbonate | SODIUM BICARBONATE | Hospira, Inc. | 0c24b592-4bc8-456f-acac-9c9525844a06 | 2026-03-09 | Warnings, Adverse reactions | 8MDF5V39QO |
| Sodium Bicarbonate 5 gr | SODIUM BICARBONATE | TWIN MED LLC | 12cad432-99db-4a9b-8619-82794e29409e | 2026-03-01 | Warnings | 8MDF5V39QO |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.